These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17071154)

  • 61. [Pharmacokinetic drug changes in patients with renal failure].
    Karie S; Launay-Vacher V; Kozlovskaia NL; Izzedine H; Deray G; Shilov EM
    Ter Arkh; 2005; 77(6):78-82. PubMed ID: 16078608
    [No Abstract]   [Full Text] [Related]  

  • 62. Lack of harmonisation in the classification of renal impairment in European Summaries of Product Characteristics.
    Salgado TM; Arguello B; Martinez-Martinez F; Benrimoj SI; Fernandez-Llimos F
    Intern Med J; 2015 Jun; 45(6):686-7. PubMed ID: 26059887
    [No Abstract]   [Full Text] [Related]  

  • 63. The importance of aldosterone in clinical medicine.
    NELSON DH
    Med Clin North Am; 1958 Sep; 42(5):1195-204. PubMed ID: 13599741
    [No Abstract]   [Full Text] [Related]  

  • 64. [Aldosterone. Its surgical importance].
    DETRIE P
    J Chir (Paris); 1959 Dec; 78():572-5. PubMed ID: 13816227
    [No Abstract]   [Full Text] [Related]  

  • 65. Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway.
    Zheng H; Ji J; Zhao T; Wang E; Zhang A
    Int J Mol Med; 2023 Feb; 51(2):. PubMed ID: 36524378
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Primary aldosteronism and obstructive sleep apnea: What do we know thus far?
    Loh HH; Sukor N
    Front Endocrinol (Lausanne); 2022; 13():976979. PubMed ID: 36246876
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study.
    Zhang H; Zhu B; Chang L; Ye X; Tian R; He L; Yu D; Chen H; Wang Y
    BMC Nephrol; 2022 Mar; 23(1):95. PubMed ID: 35247964
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk factors associated with disturbances of calcium homeostasis after initiation of a phosphate-restricted diet in cats with chronic kidney disease.
    Tang PK; Geddes RF; Chang YM; Jepson RE; Bijsmans E; Elliott J
    J Vet Intern Med; 2021 Jan; 35(1):321-332. PubMed ID: 33368694
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Effects of Salt and Glucose Intake on Angiotensin II and Aldosterone in Obese and Nonobese Patients with Essential Hypertension.
    Alaagib N; Sukkar M; Kardash M
    Int J Hypertens; 2020; 2020():6017105. PubMed ID: 32257423
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension.
    Muñoz-Durango N; Fuentes CA; Castillo AE; González-Gómez LM; Vecchiola A; Fardella CE; Kalergis AM
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347925
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of p53 on aldosterone-induced mesangial cell apoptosis in vivo and in vitro.
    Shi H; Zhang A; He Y; Yang M; Gan W
    Mol Med Rep; 2016 Jun; 13(6):5102-8. PubMed ID: 27109859
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.
    Viazzi F; Bonino B; Cappadona F; Pontremoli R
    Intern Emerg Med; 2016 Aug; 11(5):627-35. PubMed ID: 26984204
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Role of Aldosterone in Obesity-Related Hypertension.
    Kawarazaki W; Fujita T
    Am J Hypertens; 2016 Apr; 29(4):415-23. PubMed ID: 26927805
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
    J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.
    Hamlyn JM; Manunta P
    Adv Chronic Kidney Dis; 2015 May; 22(3):232-44. PubMed ID: 25908473
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mechanisms of disease reversal in focal and segmental glomerulosclerosis.
    Yang HC; Fogo AB
    Adv Chronic Kidney Dis; 2014 Sep; 21(5):442-7. PubMed ID: 25168834
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk.
    Brown JM; Underwood PC; Ferri C; Hopkins PN; Williams GH; Adler GK; Vaidya A
    Hypertension; 2014 Jun; 63(6):1205-11. PubMed ID: 24664291
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy.
    Orena S; Maurer TS; She L; Eudy R; Bernardo V; Dash D; Loria P; Banker ME; Tugnait M; Okerberg CV; Qian J; Boustany-Kari CM
    Front Pharmacol; 2013; 4():115. PubMed ID: 24133446
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aldosterone receptor antagonists: current perspectives and therapies.
    Guichard JL; Clark D; Calhoun DA; Ahmed MI
    Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The metabolic syndrome and risk of chronic kidney disease: pathophysiology and intervention strategies.
    Laguardia HA; Hamm LL; Chen J
    J Nutr Metab; 2012; 2012():652608. PubMed ID: 22523674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.